Vasculitis & polymyalgia rheumatica
Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial
An erratum to this article was published (Rheumatology (Oxford), 30 Jun 2026 ↗)
Authors' conclusion
Baricitinib is effective in patients with TAK resistant to conventional treatments and anti-TNF-α therapy and demonstrates a notable steroid-sparing effect.
Study context
- Population
- Patients with TAK unresponsive to at least 6 months of TNFi; median age 29 years, median disease duration 56.5 monthsnine female, one male
- Participants
- 10 patients
- Outcome
- Overall response (ORR) (CR plus PR)
- Follow-up
- 24 weeks
Methodological detailsmulticentre, February 2021 to August 2023
- Multicentre
- February 2021 to August 2023
Main finding
As reported in the abstract
ORR (CR plus PR)
Overall response (ORR) at 24 weeks
80%
CR
6 patients
PR
2 patients
Further findings
Disease progression · 24 weeks
- Disease progression in the remaining patients
- 2
Median GC dosage · baseline to 24 weeks
- Median GC dosage at baseline, mg/day (15.0, 26.3)
- 20.0
- Median GC dosage at 24 weeks, mg/day (4.4, 10.6)
- 6.3
- Change vs baseline
- P < 0.001
Disease activity, ESR and CRP · 24 weeks
- Significantly decreased compared with baseline
Relapse among responders
- No relapse in the eight patients who achieved a response
Safety
Upper respiratory tract infection
- Upper respiratory tract infection, n
- 2
Diarrhoea
- Diarrhoea, n
- 1
Serious adverse effects (AEs)
- No serious AEs reported
Original publication
Baricitinib for Takayasu arteritis refractory to TNF-α inhibitors: a multicentre, single-arm trial. Rheumatology (Oxford). Published 24 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →